UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (11), p.3493-3498

2015

Volltextzugriff (PDF)

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

Cancer letters, 2012-07, Vol.320 (1), p.48-55

2012

Volltextzugriff (PDF)

Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility

PloS one, 2015-09, Vol.10 (9), p.e0138616

2015

Volltextzugriff (PDF)

Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey

Toxicology (Amsterdam), 2012-11, Vol.301 (1-3), p.13-20

2012

Volltextzugriff (PDF)

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

Journal of experimental & clinical cancer research, 2012-03, Vol.31 (1), p.26-26, Article 26

2012

Volltextzugriff (PDF)

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

PloS one, 2013-06, Vol.8 (6), p.e67258-e67258

2013

Volltextzugriff (PDF)

Patient-derived xenografts reveal limits to PI3K/mTOR-and MEK-mediated inhibition of bladder cancer

Cancer chemotherapy and pharmacology, 2014-03, Vol.73 (3), p.525-538

2014

Volltextzugriff (PDF)

Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

Clinical cancer research, 2012-09, Vol.18 (18), p.5008-5019

2012

Volltextzugriff (PDF)

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

Cancer chemotherapy and pharmacology, 2014-03, Vol.73 (3), p.525-538

2014

Volltextzugriff (PDF)

[18F]FLT-PET Imaging Does Not Always Light Up Proliferating Tumor Cells

Clinical cancer research, 2012-03, Vol.18 (5), p.1303-1312

2012

Volltextzugriff (PDF)

Urethral Bulking With Polymethylmethacrylate Microspheres for Stress Urinary Incontinence: Tissue Persistence and Safety Studies in Miniswine

Urology (Ridgewood, N.J.), 2011-04, Vol.77 (4), p.1005.e1-1005.e7

2011

Volltextzugriff (PDF)

Flow cytometry in preclinical drug development

Methods in molecular biology (Clifton, N.J.), 2010, Vol.598, p.303

Lappin, Patrick B

2010

Volltextzugriff (PDF)

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

Cancer chemotherapy and pharmacology, 2012-08, Vol.70 (2), p.213-220

2012

Volltextzugriff (PDF)

Contrast Agents for Quantitative MicroCT of Lung Tumors in Mice

Comparative medicine, 2013-12, Vol.63 (6), p.482-490

2013

Volltextzugriff (PDF)

Comparison of dynamic contrast‐enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF‐03084014 and sunitinib

Cancer medicine (Malden, MA), 2014-06, Vol.3 (3), p.462-471

2014

Volltextzugriff (PDF)

Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers

Applied immunohistochemistry & molecular morphology, 2014-03, Vol.22 (3), p.188-199

2014

Volltextzugriff (PDF)

Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic

The Journal of immunology (1950), 2012-08, Vol.189 (3), p.1467-1479

2012

Volltextzugriff (PDF)

Abstract 1512: Sunitinib-induced metastasis is tumor dependent and is mediated by c-Met/HGF pathway

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1512-1512

2012

Volltextzugriff (PDF)

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Arthritis and rheumatism, 2003-11, Vol.48 (11), p.3253-3265

2003

Volltextzugriff (PDF)

Hypertrophy and Prolonged DNA Synthesis in Smooth Muscle Cells Characterize Pulmonary Arterial Wall Thickening After Monocrotaline Pyrrole Administration to Rats

Toxicologic pathology, 1997-07, Vol.25 (4), p.372-380

1997

Volltextzugriff (PDF)

Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.130-130

2015

Volltextzugriff (PDF)

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C253-C253

2013

Volltextzugriff (PDF)

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras^sup G12D-LSL^ mice

Cancer chemotherapy and pharmacology, 2012-08, Vol.70 (2), p.213

2012

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility

Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

Patient-derived xenografts reveal limits to PI3K/mTOR-and MEK-mediated inhibition of bladder cancer

Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

[18F]FLT-PET Imaging Does Not Always Light Up Proliferating Tumor Cells

Urethral Bulking With Polymethylmethacrylate Microspheres for Stress Urinary Incontinence: Tissue Persistence and Safety Studies in Miniswine

Flow cytometry in preclinical drug development

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

Contrast Agents for Quantitative MicroCT of Lung Tumors in Mice

Comparison of dynamic contrast‐enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF‐03084014 and sunitinib

Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic

Abstract 1512: Sunitinib-induced metastasis is tumor dependent and is mediated by c-Met/HGF pathway

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Hypertrophy and Prolonged DNA Synthesis in Smooth Muscle Cells Characterize Pulmonary Arterial Wall Thickening After Monocrotaline Pyrrole Administration to Rats

Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras^sup G12D-LSL^ mice

Suchergebnisse filtern